First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial
- 56 Downloads
Panitumumab is extensively used for RAS-WT metastatic colorectal cancer. This study assessed the efficacy and safety of panitumumab plus first-line chemotherapy [docetaxel (DOC) and cisplatin (CIS)] in treatment-naïve advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma (ADC) patients.
Phase II, open-label, single-arm study includes treatment-naïve advanced gastric or GEJ-ADC patients from ten Spanish centres. Patients received panitumumab (6 mg/kg) plus DOC and CIS (50 mg/m2 both) every 2 weeks until disease progression, unacceptable toxicity, or patient withdrawal. Primary endpoint: objective response rate (ORR); main secondary endpoints: disease control rate (DCR), duration of response (DoR), time to progressive disease (TTP), progression-free-survival (PFS), overall survival (OS), and safety.
Forty-four patients were included; median age: 67.8 (range 43.3–82.7) years, 68.2% male. The ORR was 27.3% (95% CI 15.0, 42.8); median PFS and OS: 5.0 (95% CI 3.6, 6.9) and 7.2 (5.5, 9.0) months, respectively. Median TTP, DCR and DoR: 5.3 (range 3.8–7.0) months, 70.5% (95% CI 54.8, 83.2%), and 4.8 (1.8, NE) months. Median panitumumab treatment duration: 11.9 (range 0.1–34.9) weeks; 25.0% patients had a dose reduction and 40.9% discontinued treatment. Grade 3–4 adverse events (AEs): 68.2%/22.2% patients. Most common AEs: asthenia (75.0%) and mucosal inflammation (54.5%). Serious AEs were experienced by 54.6% patients; 9.1%, 13.6%, and 15.9% related to panitumumab, DOC, and CIS, respectively. Three (6.8%) patients died due to AEs not related to study treatment.
The addition of panitumumab to standard chemotherapy as the first-line treatment in advanced gastric or GEJ-ADC does not appear to improve the efficacy outcomes.
KeywordsPanitumumab Docetaxel Cisplatin Gastric cancer Gastro-oesophageal junction
Writing assistance was supported by Amgen and provided by Cristina Ceballos, MSc, Nerea Gallastegui, PhD, and Neus Valveny, PhD, from TFS Develop. The authors wish to thank to all the investigators of the SPIGA Study.
This work was supported by Amgen S.A. Amgen did not have any role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This study was approved by the Ethic Committee of Reference (Comité Ético de Investigación Clínica SERGAS, Santiago de Compostela, Spain) and the Spanish Health Authorities (AEMPS), and conducted in accordance with the principles of the Declaration of Helsinki.
Informed consent was obtained from all individual participants included in the study.
- 1.Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer. 2014.Google Scholar
- 2.Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 2012. https://globocan.iarc.fr. Accessed September 23, 2015.
- 4.Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7. https://doi.org/10.1200/JCO.2006.06.8429.CrossRefGoogle Scholar
- 5.Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastro-oesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660–7. https://doi.org/10.1200/JCO.2005.17.376.CrossRefGoogle Scholar
- 6.Kim JY, Do YR, Park KU, Kim MK, Lee KH, Bae SH, et al. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol. 2010;66:31–6. https://doi.org/10.1007/s00280-009-1130-6.CrossRefGoogle Scholar
- 7.Quintero-Aldana G, Jorge M, Grande C, Salgado M, Gallardo E, Varela S, et al. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer. Cancer Chemother Pharmacol. 2015;76:731–7. https://doi.org/10.1007/s00280-015-2839-z.CrossRefGoogle Scholar
- 10.Lordick F, Kang Y-K, Chung H-C, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:490–9. https://doi.org/10.1016/S1470-2045(13)70102-5.CrossRefGoogle Scholar
- 11.Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AFC, Frances A, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 2013;14:481–9. https://doi.org/10.1016/S1470-2045(13)70096-2.CrossRefGoogle Scholar
- 13.Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101:1261–8. https://doi.org/10.1038/sj.bjc.6605319.CrossRefGoogle Scholar
- 15.Gold PJ, Goldman B, Iqbal S, Leichman LP, Zhang W, Lenz H-J, et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol. 2010;5:1472–6. https://doi.org/10.1097/JTO.0b013e3181e77a92.CrossRefGoogle Scholar